(CIDRAP News) – Xoma Ltd., a Berkeley, Calif., pharmaceutical company, recently announced that it received a $65 million multiyear federal contract to fund work on botulinum antitoxins, one of which it hopes to put through safety and efficacy tests starting in 2009.